Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Editing the fetal γ-globin promoters in hematopoietic stem cells from sickle cell disease patients induces therapeutic γ-globin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 LRF-binding site disruption induces γ-globin expression in HUDEP-2 cells. (A) Schematic representation of the β-globin locus on chromosome 11, depicting the hypersensitive sites of the locus control region (white boxes) and the HBE1, HBG2, HBG1, HBD, and HBB genes (colored boxes). The sequence of the HBG2 and HBG1 identical promoters (from −210 to −100 nucleotides upstream of the HBG TSS) is shown below. Black arrows indicate HPFH mutations described at HBG1 and/or HBG2 promoters, with the percentage of HbF in heterozygous carriers of HPFH mutations (42). The highest HbF levels were generally observed in individuals carrying SCD (*) or β-thalassemia mutations (**). LRF- and BCL11A-binding sites [as described in (11)] are highlighted by orange and green boxes, respectively. The −114/−102 13-bp HPFH deletion is indicated by an empty box. Red arrows indicate the gRNA cleavage sites. (B to E) Globin expression analyses were performed in mature erythroblasts differentiated from Cas9-GFP+ HUDEP-2 cells. Results are shown as means ± SEM of three to four independent experiments. (B) RT-qPCR quantification of (Gγ + Aγ)- and β-globin transcripts. mRNA levels were expressed as percentage of (γ + β) globins, after normalization to α-globin mRNA levels. (C) Representative flow cytometry plots showing the percentage of HbF+ cells. (D) RP-HPLC analysis of globin chains. β-Like globin expression was normalized to α-globin. Representative RP-HPLC chromatograms are reported together with the expression of γ-globin chains (in brackets). The ratio of α chains to non–α chains was similar between HBG-edited and control samples. (E) ChIP-qPCR analysis of H3K27Ac at HBB and HBG promoters in −197-edited HUDEP-2 cells and control AAVS1–edited samples (day 5 of differentiation, n = 3). ChIP was performed using an antibody against H3K27Ac and the corresponding control immunoglobulin G (IgG). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 (unpaired t test). SSC, side scatter. (F) ChIP-qPCR analysis of LRF at HBG promoters in −197-edited and control AAVS1–edited K562 cells (n = 2 biologically independent experiments). ChIP was performed using an antibody against LRF. Two different primer pairs were used to amplify the HBG promoters (A and B). KLF1 and DEFB122 served as positive and negative controls, respectively.](https://figures.cochat.ai/paper-figures/2fc47826f09a43f2bc36ffa2fad643e4/editing-a-globin-repressor-binding-site-restores-fetal-hemoglobin-synthesis-and-figure-1.jpg)


![Fig. 4 Editing efficiency in repopulating HSPCs. (A) Engraftment of human cells in NSG mice transplanted with untreated (UT) and edited mobilized healthy donor CD34+ cells (n = 4 mice for each group) 16 weeks after transplantation. Engraftment is represented as percentage of human CD45+ cells in the total murine and human CD45+ cell population, in bone marrow (BM), spleen, thymus, and blood. Values shown are means ± SEM; *P ≤ 0.05 versus untreated [one-way analysis of variance (ANOVA)]. (B) Editing efficiency in the bone marrow– and spleen-derived human CD45+ progeny of repopulating HSPCs, as evaluated by Sanger sequencing and TIDE analysis. The proportion of edited alleles in the input HSPC populations (〇: HSPCs cultured for 6 days in “HSPC medium”; □: BFU-E; △: CFU-GM) is indicated (input). Values shown are means ± SEM. Each data point represents an individual mouse. (C) Genome editing efficiency in the input populations and in bone marrow– and spleen-derived human CD45+ populations edited with the −197, −196, or −115 gRNAs, as evaluated by Sanger sequencing and TIDE analysis. The main events associated with MH-motifs are indicated. Values shown are means ± SEM (n = 4 mice per group). ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus input (unpaired t test).](https://figures.cochat.ai/paper-figures/c685de666b35421eaf08718520f7cc06/editing-a-globin-repressor-binding-site-restores-fetal-hemoglobin-synthesis-and-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Disruption of BCL11A and ZBTB7A binding sites led to 30% to 40% g globin and 75% to 80% F-cells.27”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Natural mutations and clustered regulary interspaced short palindromic repeat (CRISPR)-Cas9 disruption of the BCL11A and ZBTB7A binding sites are associated with a large effect on expression of the g-globin genes.12,21,27”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Self-citationGUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 8×
“Library preparation was performed using the original adapters and primers according to previous work (27).”
BackgroundMethodInfluentialHaeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1012-2 · Cited by 1,756
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Inference of CRISPR Edits from Sanger Trace Data
Conant, D., Hsiau, T., Rossi, N., Oki, J., Maures, T., Waite, K., Yang, J., Joshi, S., Kelso, R., Holden, K., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0113 · Cited by 804
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationEx vivo generation of fully mature human red blood cells from hematopoietic stem cells
Giarratana, M.-C., Kobari, L., Lapillonne, H., Chalmers, D., Kiger, L., Cynober, T., Marden, M. C., Wajcman, H., & Douay, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1047 · Cited by 574
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Research works printed but not linked: 1
- 10.1016/j.ymthe.2018.10.008 · DOI · Paper page
Cited by
Items 101–142 of 142
George, A., Sadanandan, P., Ravi, N. S., Vaishnavi, B., Marepally, S. K., Thangavel, S., Velayudhan, S. R., Srivastava, A., & Mohankumar, K. M. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102347 · Cited by 5
Chumchuen, S., Pornsukjantra, T., Innachai, P., Khamphikham, P., Wongborisuth, C., Anurathapan, U., Songdej, D., Sripichai, O., Tangprasittipap, A., & Hongeng, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-30762-3 · Cited by 5
Lotfi, M., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00739-6 · Cited by 5
Role of gene therapy in sickle cell disease
Raghuraman, A., Lawrence, R., Shetty, R., Avanthika, C., Jhaveri, S., Pichardo, B. V., & Mujakari, A. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101689 · Cited by 7
Fereydani, N. M., Galehdari, H., Hoveizi, E., Alghasi, A., Ajami, M., Andashti, B., & Malayeri, A. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01465-x · Cited by 4
Chalumeau, A., Antoniou, P., Dames, M. B., Martinucci, P., Retana, E., Gupta, P., Firth, M. A., Reddivari, M., Chandran, A. S., Yen, J. S., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102974 · Cited by 4
Self-citationA non-IMiD multi-target degrader reactivates fetal hemoglobin
Liu, J., Shen, Z., Park, S., Dong, Y., Yu, N., Zeng, J., Lee, H., Pate, B., Adamia, S., Vanuytsel, K., et al. (2026) · Experimental Hematology and Oncology · doi:10.1101/2025.09.17.676148 · Cited by 4
Exome sequencing in high and low fetal haemoglobin Arab–Indian haplotype sickle cell disease
Al-Nafie, A. N., Al-Ateeq, S., Al‐Muhanna, F., Alsulaiman, A. M., Alfarhan, M. F. A., Buali, W., Vatte, C., Cyrus, C., Keating, B. J., Al‐Ali, A. K., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17542 · Cited by 5
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 4
Single-strand deaminase-assisted editing for functional RNA manipulation
Zhuang, Y., Zhu, Q., Wu, H., Lin, X., Yan, Y., Geng, P., Yang, R., Shen, R., Zhang, Y., Lei, Z., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02956-7 · Cited by 3
Finotti, A., Gasparello, J., Zuccato, C., Cosenza, L. C., Fabbri, E., Bianchi, N., & Gambari, R. (2023) · Genes · doi:10.3390/genes14101927 · Cited by 3
Base editing of β 0 -thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies
Hardouin, G., Martinucci, P., Scaramuzza, S., Antoniou, P., Corradi, F., Tachtsidi, A., Corre, G., Mombled, M., Chermont, J., Manceau, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt8617 · Cited by 4
Self-citationManco, L., Santos, R., Rocha, C. I. S. A., Relvas, L., Bento, C., Maia, T. M., Gomes, V., Amorim, A., & Prata, M. J. (2022) · Hemoglobin · doi:10.1080/03630269.2022.2070498 · Cited by 3
Transcriptional regulators of fetal hemoglobin
dos Santos, G. P., Rabi, L. T., Bezerra, A. A., da Cunha, M. R., Iatecola, A., & Fernandes, V. A. R. (2024) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2024.06.001 · Cited by 3
Gene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
Gene therapies on the horizon for sickle cell disease: a clinician’s perspective
Butt, H., & Tisdale, J. F. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2386366 · Cited by 2
Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective
Amendola, M., Bedel, A., Buj‐Bello, A., Carrara, M., Concordet, J., Frati, G., Gilot, D., Giovannangeli, C., Gutiérrez-Guerrero, A., Laurent, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.191 · Cited by 2
Self-citationNew Gene Therapy Strategy for β-Thalassemia
Liang, D., Schmidt‐Wolf, I. G. H., & Pu, J. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11132-6 · Cited by 1
Yoo, B., Betancourth, D., Cao, M., Karsenty, C. L., Prasca-Chamorro, D., Pham, Q.-K., Zhang, Y., Pendergast, M. A., Sheehan, V., Park, S. H., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100537 · Cited by 1
Sickle cell anemia: HBB haplotypes; clinical heterogeneity; iPSC modeling
Vanuytsel, K., Steinberg, M. H., & Murphy, G. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-822227-0.00002-8 · Cited by 1
Drépanocytose : réveiller la globine-gamma contre la globine-bêta
Manus, J.-M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30248-3
Genome‐Editing Applications in Stem Cell Engineering and Regenerative Medicine
Gupta, P., Jaitly, S., Thakur, P., Goswami, S. G., Bhargava, N., & Ramalingam, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch17
Ramadier, S. (2020) · theses.fr (ABES) · doi:10.70675/b75724f6zb386z4f05zae5dzc8f17b350499
Sécurisation de la thérapie génique par CRISPR-Cas9 dans les pathologies du globule rouge
Boutin, J. (2021) · theses.fr (ABES) · doi:10.70675/aa1d0b59z401cz4506zacd4z39e9fd3c090b
Ahmadifard, A., Maroofi, N., Tehrani, M. M., Dabestani, T., Maleki, M. S. M., Bayrami, S., & Banan, M. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.7.33
Strouboulis, J., & Shangaris, P. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.009
Godard, A. (2023) · theses.fr (ABES) · doi:10.70675/dd16fc9eza9e8z454az8c68z56e5bd7363e1
CRISPR/Cas9 gene editing for treating gene and protein disorders
Umeyor, C. E., Negi, P., Agarwal, R., Hanjankar, S. N., & Patravale, V. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00004-6
Silva, P. E. B. D. S., Araújo, P. L., Costa, F. M. D., & Santos, P. D. S. (2025) · Revista Interdisciplinar. · doi:10.29327/2393773.1.18-20
Modern therapeutic approaches for β-thalassemia: from blood transfusion to gene therapy
Dolgushina, E. N., Коптева, О. С., Shakirova, A. L., Lepik, K. V., Bykova, T. A., Zubarovskaya, L. S., & Kulagin, A. (2026) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2025-12-3-56-67
Gene-Editing-Based Approaches for Curing Sickle Cell Disease
Park, S. H., Karsenty, C. L., Prasca-Chamorro, D., Moyo, B., Yoo, B., & Bao, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_8 · Cited by 1
Base editing approaches for the treatment of β-hemoglobinopathies
Antoniou, P. (2021) · theses.fr (ABES) · doi:10.70675/c4dddb32zf8aez4bc3z8cf8zce9a4e808265
Yadav, S., Chakravarti, B., Anjum, B., Yadav, S., Singh, P. K., & Kumar, A. (2026) · Journal of Hematology · doi:10.14740/jh2190
Development of gene therapy approaches to ß-hemoglobinopathies
Chalumeau, A. (2023) · theses.fr (ABES) · doi:10.70675/7fc1b037zbffbz4005z9109zd81aa6f38a83
Self-citationBase editing approaches for the treatment of ß-hemoglobinopathies
Hardouin, G. (2022) · theses.fr (ABES) · doi:10.70675/593cd291z9d0ez45a6z82cdz64ffb2e65ff8
Self-citationGenome and epigenome editing approaches to treat β-hemoglobinopathies
Fontana, L. (2024) · theses.fr (ABES) · doi:10.70675/f1623d8bz5529z4d2dzb255z45ed273f643c
CRISPR and Fanzor in sickle cell disease: current progress and future prospects
Humoudi, A. Y. A., Alotaibi, A. G., Alosaimi, N. F., Alshalani, A., Alqahtani, S. D., Alsaab, S. M., Almutiri, B. J., & Albariqi, M. M. H. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1774014
UCA1 lncRNA regulates γ-globin expression by modulating the miR-148b/BCL11A axis
Rahaman, M., Bhattacharya, S., Mukherjee, M., Bhowmick, C., Shukla, P. C., Dolai, T. K., & Chakravorty, N. (2026) · Life Science Alliance · doi:10.26508/lsa.202603620
Mechanisms underlying disease-causing variants in promoters and enhancers
Long, H. K., Wu, K., Barkham, R. S., & Bickmore, W. A. (2026) · Nature Genetics · doi:10.1038/s41588-026-02743-3
Hassan, M. S., Hoque, M., & Ali, S. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102662
Lu, D., Xu, Z., Peng, Z., Yang, Y., Song, B., Xiong, Z., Ma, Z., Guan, H., Chen, B., Nakamura, Y., et al. (2022) · doi:10.3389/fgene.2022.881937.s001
Metadata
- Authors
- Weber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., Mavilio, F., Amendola, M., Andre-Schmutz, I., Cereseto, A., El Nemer, W., Concordet, J.-P., Giovannangeli, C., Cavazzana, M., & Miccio, A.
- Affiliations
- Inserm (FR)
- Laboratory of chromatin and gene regulation during development, INSERM UMR1163, Paris, France.
- University of Trento (IT)
- Paris-Descartes Bioinformatics Platform, Imagine Institute, Paris 75015, France.
- INSERM U1154, CNRS UMR7196, Museum National d’Histoire Naturelle, Paris, France.
- University of Modena and Reggio Emilia (IT)
- Laboratory of Human Lymphohematopoiesis, INSERM UMR1163, Paris, France.
- Biologie Intégrée du Globule Rouge UMR_S1134, Inserm, Univ. Paris Diderot, Sorbonne Paris Cité, Univ. de la Réunion, Univ. des Antilles, Paris, France.
- Centre National de la Recherche Scientifique (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Weber, Leslie
- Frati, Giacomo
- Miccio, Annarita
- ORCID
- Venue
- Science Advances
- Published
- 2020-02-14
- Volume
- 6
- Issue
- 7
- Pages
- eaay9392
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7015694
- OpenAlex
- W3006567544
- Semantic Scholar
- 52b26144b0ee0a8db71bd718acdc5bf17daaa068
- Cited by
- 140
- References
- 53
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 20 · 2023: 26 · 2022: 19 · 2021: 30 · 2020: 15
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by-nc)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- European Research Council
- Agence Nationale de la Recherche
- Genopole
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- sickle cell disease, fetal hemoglobin, CRISPR/Cas9 genome editing, hematopoietic stem and progenitor cells, xenotransplantation, promoter editing
- MeSH terms
- Gene Editing, Anemia, Sickle Cell, Binding Sites, Fetal Hemoglobin, Humans, Phenotype, beta-Thalassemia, beta-Globins, gamma-Globins, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.